medigraphic.com
ISSN 1561-302X (Print)

2016, Number 4

<< Back Next >>

Rev cubana med 2016; 55 (4)

Biomarkers of renal damage in essential hypertension

León ÁJL, García SN, Gutiérrez RÁ, Pérez CMD

Language: Spanish
References: 25
Page: 297-310
PDF size: 136.42 Kb.


ABSTRACT

Introduction: Evaluation of renal damage in patients with essential hypertension is a diagnostic challenge, because it is asymptomatic for many years. Biomarkers of renal damage may represent an option in their early detection.
Objective: Evaluate the biomarker behavior of renal damage in patients with uncomplicated arterial hypertension, its relation to overall cardiovascular risk and its time of evolution.
Methods: 100 patients with essential arterial hypertension without target organ lesion were studied. All patients underwent clinical history, microalbuminuria, uric acid, creatinine, glomerular filtration with the MDRD formula, cystatin C, glomerular filtration with cystatin C with the Grubb formula, total cholesterol, and global cardiovascular risk were estimated.
Results: No relationship was found between microalbuminuria, cardiovascular risk and duration of hypertension (p = 0.926 and p = 0.157). As cardiovascular risk increased, glomerular filtration values MDRD and glomerular filtration with cystatin C with the Grubb formula (p = 0.456 and p = 0.14) decreased. There was no relationship between the time of evolution of hypertension, glomerular filtration MDRD and glomerular filtration with cystatin C with the Grubb formula (p = 0.360 and p = 0.374). The relationship between uric acid, overall cardiovascular risk (p = 0.036) and time of evolution of hypertension (p = 0.009) was established.
Conclusions: These results validate that microalbuminuria, glomerular filtration MDRD and glomerular filtration with the Grubb formula were not statistically significant with overall cardiovascular risk and the duration of hypertension, but serum uric acid was. Glomerular filtration values MDRD and glomerular filtration with cystatin C with the Grubb formula demonstrate its usefulness to assess kidney damage in the patients studied.


REFERENCES

  1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.

  2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC. Guidelines for the management of arterial hypertension: The task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357.

  3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.

  4. Stevens PE, Levin A . Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30.

  5. Waxman S, Ishibashi F, Muller JE. Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events. Circulation. 2006;114(22):2390-411.

  6. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33(13):1635-701.

  7. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749-57.

  8. Grubb AO, Cystatin C. Properties and use as diagnostic marker. Adv Clin Chem. 2001;35:63-99.

  9. Elosua R, Morales Salinas A. Determinación del riesgo cardiovascular total. Caracterización, modelización y objetivos de la prevención según el contexto sociogeográfico. Rev Esp Cardiol. 2011;11(supl):(E):2-12.

  10. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Rev Esp Cardiol. 2008;61(1):1-49.

  11. Bonet Gorbea M, Varona Pérez P. III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no trasmisibles. Cuba 2010-2011. La Habana: Editorial Ciencias Médicas; 2014.

  12. Samet JM, Yoon SY. Gender, women, and the tobacco epidemic [homepage en Internet]; Editorial Geneva: World Health Organization, 2010 [citado 20 de Julio de 2016]. Disponible en: http://www.who.int/iris/handle/10665/44342

  13. Tchernof A, Després JP . Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404.

  14. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA , et al. 2013 AHA/ACC/TOS. Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 suppl 2):S102-38.

  15. Bharati V. Mittal, Hypertension in the Developing World: Challenges and Opportunities. American Journal of Kidney Diseases. 2010;55(3):590-8.

  16. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32-5.

  17. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation Between Kidney Function, Proteinuria, and Adverse Outcomes. JAMA. 2010;303(5):423-9.

  18. Rodilla E, Costa JA, Pérez Lahiguera F, González C, Miralles A, Pascual JM. Relación del cistatina C con otros parámetros de riesgo vascular en pacientes con hipertensión arterial. Med Clin (Barc). 2008;130(1):1-5.

  19. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-60.

  20. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of Cystatin C with Mortality, Cardiovascular Events, and Incident Heart Failure among Persons with Coronary Heart Disease: Data from the Heart and Soul Study. Circulation. 2007;115(2):173-9.

  21. Shlipak MG, Matsushita K, Arnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-43.

  22. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416-21.

  23. Ofori SN, Odia OJ . Serum uric acid and target organ damage in essential hypertension. Vasc Health Risk Manag. 2014;10:253-61.

  24. Sedaghat S, Hoorn EJ, van Rooij FJ, Hofman A, Franco OH, Witteman JC, et al. Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One. 2013;8(11):e76827.

  25. Dawson J, Jeemon P, Hetherington L, Judd C, Hastie C, Schulz C, et al. Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. Hypertension. 2013;62(1):105-11.




2020     |     www.medigraphic.com